Share on StockTwits

Immunomedics (NASDAQ:IMMU) was downgraded by R. F. Lafferty from a “buy” rating to a “neutral” rating in a research note issued on Wednesday. They currently have a $4.00 price objective on the stock. R. F. Lafferty’s target price indicates a potential upside of 19.76% from the stock’s previous close.

Shares of Immunomedics (NASDAQ:IMMU) traded down 0.30% during mid-day trading on Wednesday, hitting $3.3299. 296,707 shares of the company’s stock traded hands. Immunomedics has a one year low of $3.04 and a one year high of $7.35. The stock has a 50-day moving average of $3.37 and a 200-day moving average of $3.89. The company’s market cap is $296.8 million.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Monday, August 25th. The company reported ($0.13) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.01. The company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.20 million. On average, analysts predict that Immunomedics will post $-0.44 earnings per share for the current fiscal year.

Immunomedics, Inc is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Receive News & Ratings for Immunomedics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.